Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding.
July 2023
|
November 11, 2021
|
September 28, 2023
Cantor Global Healthcare Conference
|
September 13, 2023
FORCE Family Office Webinar
|
June 7, 2023
Jefferies 2023 Healthcare Conference
|
BETHESDA, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer of Gain Therapeutics, will deliver a featured presentation at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference: Drug Discovery for Progressive Central Nervous...
First drug candidate identified with Gain’s proprietary computational drug discovery platform SEE-Tx® to enter clinical development phase BETHESDA, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company has received approval from the Bellberry Human Research Ethics Committee (HREC) in...
Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function Data presentedat the International Congress of Parkinson's Disease and Movement Disorders® Gain remains on track to begin a Phase 1 clinical study of GT-02287 later this year BETHESDA, Md., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”),...
Contact IR
Company
GAIN THERAPEUTICS INC.
4800 Montgomery Lane Ste
220 Bethesda, MD 20814,
Phone: +1 301 500 1556